Dr. Song is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
NKGen Biotech
3001 Daimler St
Santa Ana, CA 92705Phone+1 310-310-1992
Summary
- I am a board certified radiation oncologist and biotech executive.
Education & Training
University of Chicago/University of Illinois College of Medicine at ChicagoResidency, Radiation Oncology, 1992 - 1996
St Barnabas Medical CenterInternship, Transitional Year, 1991 - 1992
George Washington University School of Medicine and Health SciencesClass of 1991
Certifications & Licensure
CA State Medical License 2007 - 2026
IL State Medical License 1992 - 2014
NV State Medical License 2005 - 2009
VA State Medical License 1996 - 2008
SC State Medical License 1995 - 1996
American Board of Radiology Radiation Oncology
Clinical Trials
- Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Start of enrollment: 2019 Jul 15
Publications & Presentations
PubMed
- Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study.Clemente Humberto Zúñiga, Blanca Isaura Acosta, Rufino Menchaca, Cesar A Amescua, Sean Hong
Alzheimer's Research & Therapy. 2025-02-12 - 4 citationsManagement of radiation-induced mucosal necrosis with photobiomodulation therapy.Joel B. Epstein, Paul Y. Song, Allen S. Ho, Babak Larian, Arash Asher
Supportive Care in Cancer. 2018-05-04 - 7 citationsPhotobiomodulation therapy: management of mucosal necrosis of the oropharynx in previously treated head and neck cancer patientsJoel B. Epstein, Paul Y. Song, Allen S. Ho, Babak Larian, Arash Asher
Supportive Care in Cancer. 2017-04-01
Press Mentions
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use ProgramFebruary 21st, 2025- NKGen's Troculeucel Therapy Demonstrates Stability and Cognitive Improvement in AD TrialFebruary 13th, 2025
- NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s DiseaseFebruary 13th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
